Loading...
Loading...
MVC Capital, Inc.
MVC
(the "Company"), a publicly traded business development company that makes
private debt and equity investments, announced today the completed sale of a
portfolio company, Summit Research Labs ("Summit"), a specialty chemical
company that manufactures and markets antiperspirant actives globally, to an
affiliate of One Rock Capital Partners, LLC.
MVC received gross equity proceeds of $66 million, realizing a gain of $50
million from the transaction, a $3.5 million premium to the last reported fair
market value placed on Summit by the Company's Valuation Committee as of
January 31, 2013. This transaction reflects a 31% gross IRR^1 for MVC since
the time of its original investment in Summit in August 2006. The gross IRR
includes all fees and distributions received from its equity position in
Summit over the life of the investment. MVC also received $16.5 million in
gross debt proceeds from its original $8.0 million second lien loan provided
to Summit.
As part of the agreement, MVC provided Summit with a new, $22 million second
lien loan, which matures in five and a half years.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsAsset Sales
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in